Search clinical trials for: palivizumab

Total 32 results

Merck Sharp & Dohme LLC

Recruiting

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

RSV Infection

United States, Australia, Canada, Chile, Colombia, Czechia, Germany, Greece, Malaysia, Mexico, New Zealand, Puerto Rico, Singapore, South Africa, Spain, Taiwan, Turkey, United Kingdom, Japan, Peru, Hong Kong, France, Thailand, Finland, ... and more
Cardiff Oncology

No longer available

Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | KRAS Gene Mutation
mAbxience Research S.L.

Completed

Pharmacokinetic Study Comparing MB05 (Proposed Palivizumab Biosimilar), EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.

Healthy Volunteers

Australia, New Zealand
AstraZeneca

Completed

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Respiratory Syncytial Virus Infections

United States, France, Italy, Spain, Belgium, Russian Federation, Poland, Turkey, New Zealand, Austria, Korea, Republic of, Germany, Hungary, Bulgaria, Ukraine, South Africa, Japan, Estonia, Lithuania, United Kingdom, Canada, Czechia and more
Kosuyolu Heart Hospital
Kocaeli University; Sakarya University; Sabanci University; Maras Necip Fazil City... and other collaborators

Completed

Adherence to Palivizumab Prophylaxis

Congenital Heart Disease in Children | RSV

Turkey
mAbxience Research S.L.

Completed

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Healthy Adult Participants

United Kingdom
Bial - Portela C S.A.

Completed

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil

Pulmonary Arterial Hypertension

Germany
AbbVie (prior sponsor, Abbott)

Completed

Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

Respiratory Syncytial Virus Infections
MedImmune LLC

Completed

Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)

Chronic Lung Disease

United States
Sunnybrook Health Sciences Centre
Abbott

Completed

Utilization and Compliance of Respiratory Syncytial Virus Monoclonal Antibody Therapy

Respiratory Syncytial Virus Infections | Lower Respiratory Tract Infection

Canada
AbbVie

Completed

A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus (Synagis Russia)

Respiratory Syncytial Virus (RSV)
Hamad Medical Corporation

Completed

"Palivizumab Therapy for RSV-bronchiolitis"

Respiratory Syncytial Virus-bronchiolitis

Qatar
AbbVie

Completed

Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®

Respiratory Syncytial Virus Infection
AbbVie

Completed

Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis (SUNRISE)

Respiratory Syncytial Virus (RSV)
Rambam Health Care Campus

Completed

Prospective Evaluation of the Efficacy of Palivizumab Administration in Children Born at 29-32 Weeks of Gestation

Bronchial Hyperreactivity | Infant, Premature

Israel
Fraser Health

Completed

Tetracaine Compared to Placebo for Reducing Pain With Palivizumab - A Pilot Study

Pain

Canada
Tokai University
Scientific Committee for Elucidation of Infantile Asthma

Completed

Effects of Preventive Treatment for Respiratory Syncytial (RS) Virus Infection During Infancy on Later Atopic Asthma in Preterm Infants

Recurrent Wheezing | Atopic Asthma
AbbVie (prior sponsor, Abbott)
Fundasamin (Argentina)

Completed

A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America

Respiratory Syncytial Virus Infection

Argentina, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
AbbVie (prior sponsor, Abbott)

Completed

Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions

Respiratory Syncytial Virus Infection

Japan
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Motavizumab Administration for a Second Season for RSV Prophylaxis

Chile, Brazil
MedImmune LLC

Completed

Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season

Respiratory Syncytial Virus Infections | Chronic Lung Disease and <= 24 Months of Age or | Premature With Gestational Age <=35 Weeks and <=6 Months of Age

Australia, Chile, New Zealand
Abbott

Completed

Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection (INSPIRA)

Respiratory Syncytial Virus Infection

Peru
Abbott
Assign Data Management and Biostatistics GmbH

Completed

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

Premature Infants

Austria
Valduce Hospital

Unknown

Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate?

Colonic Adenomas

Italy
Satoshi Kusuda
Scientific Committee of Recurrent Wheezing

Completed

Effect of Palivizumab on Later Recurrent Wheezing in Preterm Infants

Asthma | Wheezing | Recurrent Wheezing

Japan
MedImmune LLC

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Congenital Heart Disease

United States, Spain, United Kingdom, Canada, Belgium, Germany, Israel, Austria, Poland, Russian Federation, Sweden, Lebanon, France, Czech Republic, Hungary, Denmark, Bulgaria
Abbott

Completed

Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

Premature Birth | Congenital Heart Disease | Bronchopulmonary Dysplasia | Respiratory Syncytial Virus Infection

Russian Federation
Abbott

Completed

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

Severe Respiratory Syncytial Virus Infection

Austria, Belgium, France, Germany, Italy, Norway, Poland, Slovenia, Spain, United Kingdom
MedImmune LLC

Completed

A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)

-Unhealthy Children With a History of Prematurity

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Cancer

United States
MedImmune LLC

Completed

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

Respiratory Syncytial Virus Infections

United States

Search clinical trials for: palivizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Latvia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations